Back to top
more

ANI Pharmaceuticals (ANIP)

(Real Time Quote from BATS)

$64.83 USD

64.83
124,190

-1.91 (-2.86%)

Updated Jun 10, 2024 03:50 PM ET

After-Market: $65.70 +0.87 (1.34%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sarepta Inks Manufacturing Deal for Gene Therapy Program

by Zacks Equity Research

Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.

    Here's Why Sarepta is Up More Than 60% So Far This Year

    by Zacks Equity Research

    Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.

      BioMarin's Palynziq Gets FDA Approval for Phenylketonuria

      by Zacks Equity Research

      BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.

        INSYS Gets Negative FDA Recommendation for Pain Candidate

        by Zacks Equity Research

        INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.

          Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?

          by Zacks Equity Research

          Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.

            Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?

            by Zacks Equity Research

            Let's put ANI Pharmaceuticals (ANIP) stock into this equation and find out if it is a good choice for value-oriented investors right now.

              Pfizer Hikes Dividend, Announces $10B Share Buyback Plan

              by Zacks Equity Research

              Pfizer (PFE) raises quarterly dividend for 2018 while also authorizing a new $10 billion share repurchase program.

                Spectrum Doubles in 3 Months: What's Driving the Rally?

                by Zacks Equity Research

                Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.

                  ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%

                  by Zacks Equity Research

                  ANI Pharmaceuticals (ANIP) shares rose nearly 18% in the last trading session, amid huge volumes.

                    Moving Average Crossover Alert: ANI Pharmaceuticals (ANIP)

                    by Zacks Equity Research

                    ANI Pharmaceuticals, Inc. (ANIP) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

                      New Strong Buy Stocks for August 9th

                      by Zacks Equity Research

                      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                        Kevin Matras headshot

                        This Value Screen Is Our Top Performer This Year

                        by Kevin Matras

                        See how this screen has blown past the market and how you can start using it in your own portfolio. Highlighted stocks include ANIP, KCG, MDR, POWL and RRMS.

                          Brian Bolan headshot

                          5 Stocks With Incredible Growth Prospects

                          by Brian Bolan

                          A screen for 35% or more growth in revenue and earnings results in these picks!